Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
preSAVE: Sacituzumab Govitecan + Zimberelimab in MIBC
NCT06528483Phase 2Not yet recruiting
- Sponsor
- Fondazione IRCCS - Istituto Nazionale dei Tumori di Milano
- Start
- Dec 2024
- Primary completion
- Dec 2026
- Modality
- Monoclonal Antibodies, Antibody-Drug Conjugates (ADCs), Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of sacituzumab govitecan and zimberelimab in muscle-invasive bladder cancer (MIBC), sponsored by Fondazione IRCCS - Istituto Nazionale dei Tumori di Milano. Primary endpoint: Event-Free Survival at 24 months. Planned start Dec 2024; status: not yet recruiting.
02
Drugs
sacituzumab govitecanzimberelimab
03
Conditions
muscle-invasive bladder cancer (MIBC)
Beyond the preview
Go deeper on NCT06528483.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06528483.